Information Provided By:
Fly News Breaks for September 5, 2019
EOLS
Sep 5, 2019 | 05:05 EDT
Mizuho analyst Difei Yang assumed coverage of Evolus with an unchanged Buy rating and $30 price target. The company's "innovative" Jeuveau neurotoxin will capture significant share in the "attractive" neurotoxin market, Yang tells investors in a research note.
News For EOLS From the Last 2 Days
There are no results for your query EOLS